Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Basik

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Nature Medicine|September 28, 2011
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155Suhwan Chang, Rui-Hong Wang, Keiko Akagi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
Advances in Therapy|March 10, 2026
Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS StudyKaren Gambaro, Kahina Rachedi, Mark Basik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabShirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)Seema A Khan, Fengmin Zhao, Lori J Goldstein, et al.
JAMA Network Open|September 3, 2024
Universal Genetic Testing for Newly Diagnosed Invasive Breast CancerZoulikha Rezoug, Stephanie P Totten, David Szlachtycz, et al.
European Journal of Human Genetics : EJHG|October 11, 2023
"I just wanted more": Hereditary cancer syndromes patients' perspectives on the utility of circulating tumour DNA testing for cancer screeningElla Adi-Wauran, Marc Clausen, Salma Shickh, et al.
Nature Genetics|August 10, 2004
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancerPia Huusko, Damaris Ponciano-Jackson, Maija Wolf, et al.
Communications Biology|June 18, 2020
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumorsPaul Savage, Alain Pacis, Hellen Kuasne, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 8, 2013
Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicineZuanel Diaz, Adriana Aguilar-Mahecha, Eric R Paquet, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Nature Medicine|September 28, 2011
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155Suhwan Chang, Rui-Hong Wang, Keiko Akagi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
Advances in Therapy|March 10, 2026
Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS StudyKaren Gambaro, Kahina Rachedi, Mark Basik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabShirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)Seema A Khan, Fengmin Zhao, Lori J Goldstein, et al.
JAMA Network Open|September 3, 2024
Universal Genetic Testing for Newly Diagnosed Invasive Breast CancerZoulikha Rezoug, Stephanie P Totten, David Szlachtycz, et al.
European Journal of Human Genetics : EJHG|October 11, 2023
"I just wanted more": Hereditary cancer syndromes patients' perspectives on the utility of circulating tumour DNA testing for cancer screeningElla Adi-Wauran, Marc Clausen, Salma Shickh, et al.
Nature Genetics|August 10, 2004
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancerPia Huusko, Damaris Ponciano-Jackson, Maija Wolf, et al.
Communications Biology|June 18, 2020
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumorsPaul Savage, Alain Pacis, Hellen Kuasne, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 8, 2013
Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicineZuanel Diaz, Adriana Aguilar-Mahecha, Eric R Paquet, et al.
Pageof 13